5 ESSENTIAL ELEMENTS FOR ABBV-744 IN CLINICAL TRIALS FOR NON-SMALL CELL LUNG CANCER (NSCLC)

In Segment C, individuals will receive ABBV-744 and oral navitoclax. In Section D, contributors will receive ABBV-744 and ruxolitinib. Members will acquire treatment right until ailment progression or the individuals are unable to tolerate the study drugs.Doable new ways for your analysis and treatment of AML. (A) The identification of super enhanc